Direct‐acting antivirals in hepatitis C virus (<scp>HCV</scp>)‐infected and <scp>HCV</scp>/<scp>HIV</scp>‐coinfected patients: real‐life safety and efficacy

Abstract

Treatment with all-oral DAA combinations of patients infected with HCV and with HCV/HIV under real-life conditions led to high and similar rates of SVR12. Moreover, the historical factors associated with a sustained virological response to pegIFN/RBV were not predictive of the response to all-oral DAAs.